Money is flooding into exchange- traded funds focused on health care at the fastest rate in at least six years, driven by booming biotechnology and pharmaceutical sectors bringing new products to market.
Eli Lilly & Co. , already facing competition next year for its top-selling drug, lost a court bid over patent protection on its cancer medicine Gemzar , which could lead to generic products as early as November.
Les Funtleyder, president of Poliwogg's Investment Advisory division, Bloomberg senior economist Joe Brusuelas, and Ben Willis, managing director at Albert Fried & Co. LLC., discuss the economic impact of President Obama's Affordable Care Act. Funtleyder, Brusuelas and Willis talk with Bloomberg's Courtney Donohoe on Bloomberg Radio's "Taking Stock."
Pfizer Inc. agreed to pay about $330 million to resolve claims that its Prempro menopause drug caused breast cancer, in the first large-scale settlements in eight years of litigation, two people familiar with the accords said.
Eli Lilly & Co. , already facing competition next year for its top-selling drug, lost a bid to block generic sales of the cancer medicine Gemzar after November, opening the door to rivals two years earlier than the company anticipated.
Berkshire Hathaway Inc. has been buying about 1 million shares a month of dialysis-center operator DaVita HealthCare Partners Inc., making the holding among the dozen largest at Warren Buffett’s company.